Australia's most trusted
source of pharma news
Thursday, 19 February 2026
Posted 18 February 2026 PM
Chinese prosecutors have charged AstraZeneca and two former senior executives over alleged illegal trade and unlawful collection of personal patient data, with the company facing a fine of up to AU$25 million.
The details were released in the company's financial year and Q4 earnings report which said its subsidiary, AstraZeneca Investment (China), had received a Notice of Transfer to the Prosecutor from the Shenzhen Bao’an District Public Security Bureau.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.